Abpro Holdings, INC

Abpro Holdings, Inc. has received final notification from the Nasdaq Listing and Hearing Review Council that its securities will be delisted for failure to meet minimum equity requirements.

Abpro Holdings, Inc. received multiple Nasdaq non-compliance notices regarding board and committee independence, prompting director appointments amid delisting concerns.

Abpro Holdings, Inc. secured a $147,000 unsecured loan from its CEO to cover D&O insurance premiums and appointed Dr. Byung-Hak Yoon to its Board of Directors.

Abpro Holdings, Inc. and Celltrion, Inc. announced FDA Investigational New Drug (IND) clearance for their lead multispecific antibody oncology program, ABP-102 / CT-P72, enabling a Phase 1 clinical trial.

Abpro Holdings and Celltrion submitted an Investigational New Drug application to the FDA for ABP-102/CT-P72, a T cell engager for HER2-positive cancers.

Abpro Holdings, Inc. received a Nasdaq extension to regain listing compliance, citing progress on its turnaround strategy and pipeline advancement.

Abpro Holdings reports a net loss of $1.0 million for Q1 2026 while navigating delisting and ongoing liquidity challenges.

Abpro Holdings, Inc. reported a significant net loss of $8.5 million for the nine months ended September 30, 2025, and faces delisting from Nasdaq due to non-compliance with listing requirements, raising substantial doubt about its ability to continue as a going concern.

Abpro Holdings, Inc. reported a significantly increased net loss in Q2 2025, alongside multiple Nasdaq delisting notices and a 'going concern' warning.

Abpro Holdings reports a net loss for Q1 2025 and is addressing Nasdaq listing deficiencies related to minimum bid price and market value.

Abpro Holdings, formerly Atlantic Coastal Acquisition Corp. II, released its Q3 2024 financial results, highlighting a net loss and the completion of its business combination with Abpro Corporation.

Atlantic Coastal Acquisition Corp. II reported a net loss for the second quarter of 2024 and is facing going concern issues as it works towards a business combination.

Abpro Holdings, Inc. reports continued operational challenges, including a Nasdaq delisting, while pursuing strategic financing and product development.

Abpro Holdings' 10-K filing reveals a restatement of prior financials due to accounting errors, raising concerns about the company's ability to continue as a going concern and impacting investor confidence.

Atlantic Coastal Acquisition Corp. II has filed an amendment to its annual report on Form 10-K to furnish a revised report from its independent registered public accounting firm.

Atlantic Coastal Acquisition Corp. II's 10-K filing outlines its financial status, the proposed business combination with Abpro Corporation, and associated risks.

Abpro Holdings, Inc. Director Soo Young Lee was granted 60,600 stock options with an exercise price of $0.3154.

Abpro Holdings, Inc. CEO and Chairman Miles Suk acquired 72,035 shares of common stock at an average price of $0.28 per share.

Abpro Holdings, Inc. Director and 10% Owner Anthony D. Eisenberg was granted 60,600 stock options with an exercise price of $0.3154 per share, vesting fully on November 13, 2025.

Abpro Holdings, Inc. CEO and Chairman, Suk Jin Wook (Miles), acquired 500,000 Restricted Stock Units, increasing his beneficial ownership to 646,477 shares.

Abpro Holdings CEO and Chairman Suk Jin Wook (Miles) reports the acquisition of 16,200 shares of common stock at an average price of $0.26 per share.

Abpro Holdings CEO Suk Jin Wook (Miles) reports the purchase of 4,325 shares of common stock at a weighted average price of $0.25 per share.

Abpro Holdings, Inc. amends its proxy statement to propose a 1-for-30 reverse stock split aimed at regaining compliance with Nasdaq's minimum bid price requirement and improving marketability.

Abpro Holdings, Inc. has adjourned its 2025 Annual Meeting of Stockholders until October 10, 2025, to allow more time to solicit votes and achieve a quorum.

Abpro Holdings, Inc. reminds stockholders to cast their votes for the September 18, 2025 Annual Meeting, emphasizing the importance of participation.

Abpro Holdings, Inc. will hold its Annual Meeting on September 18, 2025, to vote on the re-election of a director, ratification of its auditor, and a critical one-for-ten reverse stock split aimed at regaining Nasdaq compliance.

Abpro Holdings will hold its annual stockholders meeting virtually on May 20, 2025, to vote on the re-election of a Class I director and the ratification of its independent accounting firm.

Abpro Holdings is asking stockholders to approve the issuance of common stock to YA II PN, LTD. (Yorkville) under a Standby Equity Purchase Agreement to secure additional capital.

Abpro Holdings, a preclinical biotechnology company, filed an S-1/A to register shares for resale under a $50 million equity purchase agreement, while facing substantial doubt about its ability to continue as a going concern and multiple Nasdaq delisting notices.

Abpro Holdings, a biotechnology company, filed an S-1 registration statement for a $50 million standby equity purchase agreement, while facing substantial doubt about its ability to continue as a going concern.

Abpro Holdings, a biotechnology company, has received multiple Nasdaq delisting notices and faces substantial doubt about its ability to continue as a going concern, reporting a net loss of $3.887 million in Q1 2025 and an accumulated deficit of $120 million.

Abpro Holdings is seeking to raise up to $50 million by reselling common stock through a Standby Equity Purchase Agreement with YA II PN, Ltd.

Abpro Holdings seeks to register the issuance of warrant shares and the resale of common stock and warrants by selling securityholders, potentially amounting to a $370 million offering.

Abpro Holdings, Inc. has filed a registration statement for the resale of up to 31.8 million shares of common stock and 13.9 million warrants by existing securityholders, along with the primary issuance of up to 28.9 million shares upon warrant exercise.

Goldman Sachs Group and its subsidiary, Goldman Sachs & Co. LLC, have disclosed a 6.8% beneficial ownership stake in ABPRO HOLDINGS INC common stock.